We are live on ! Find out more
AKBA icon

Akebia Therapeutics

93 hedge funds and large institutions have $147M invested in Akebia Therapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 27

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

2% more funds holding

Funds holding: 9193 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

22% less capital invested

Capital invested by funds: $189M → $147M (-$41.9M)

41% less call options, than puts

Call options by funds: $1.94M | Put options by funds: $3.29M

Holders
93
Holders Change
+2
Holders Change %
+2.2%
% of All Funds
2.48%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
38
Reduced
27
Closed
12
Calls
$1.94M
Puts
$3.29M
Net Calls
-$1.35M
Net Calls Change
-$1.73M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
26
UBS Group
Switzerland
$774K +$245K +28,059 +37%
JIC
27
Johnson Investment Counsel
Ohio
$724K +$25.6K +2,930 +3%
Wells Fargo
28
Wells Fargo
California
$621K -$34.3K -3,934 -5%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$564K +$65K +7,446 +11%
BCM
30
Bridgeway Capital Management
Texas
$486K -$142K -16,250 -20%
TA
31
Teachers Advisors
New York
$459K +$61.5K +7,047 +13%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$441K
Millennium Management
33
Millennium Management
New York
$405K +$473K +54,183 New
AA
34
ALPS Advisors
Colorado
$399K +$93.6K +10,728 +25%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$343K +$8.06K +923 +2%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$306K +$94.3K +10,803 +36%
PAWC
37
P.A.W. Capital
Connecticut
$299K -$829K -95,000 -70%
EA
38
Emerald Acquisition
Washington
$289K +$338K +38,666 New
Creative Planning
39
Creative Planning
Kansas
$279K -$110K -12,650 -25%
MLICM
40
Metropolitan Life Insurance Company (MetLife)
New York
$254K
ProShare Advisors
41
ProShare Advisors
Maryland
$244K +$7.25K +831 +3%
TI
42
Trexquant Investment
Connecticut
$243K +$283K +32,442 New
CS
43
Credit Suisse
Switzerland
$242K +$157K +18,042 +125%
VEA
44
Virtus ETF Advisers
New York
$221K +$71.2K +8,160 +38%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$211K -$121K -13,842 -33%
Deutsche Bank
46
Deutsche Bank
Germany
$202K +$69.8K +8,001 +42%
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$196K +$61.1K +7,000 +36%
Citadel Advisors
48
Citadel Advisors
Florida
$193K +$41K +4,699 +22%
CG
49
Cutler Group
California
$189K +$2.62K +300 +1%
Dimensional Fund Advisors
50
Dimensional Fund Advisors
Texas
$187K -$812 -93 -0.4%

AKBA Hedge Fund Activity: Q2 2016 in Review

93 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2016, worth a combined $147M — down 22% from $189M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new AKBA positions and 12 closed out — a net gain of 2 holders — while 38 added to existing stakes and 27 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $5.43M. The largest seller was Visium Asset Management, cutting an estimated $12.1M.

  • 93 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2016, up from 91 in Q1 2016.
  • Funds reported $147M of Akebia Therapeutics stock for Q2 2016, down 22% quarter-over-quarter.
  • 14 funds opened new Akebia Therapeutics positions in Q2 2016 and 12 closed out, a net change of +2 holders.
  • The largest Akebia Therapeutics buyer in Q2 2016 was Avoro Capital Advisors, an estimated $5.43M added.
  • The largest Akebia Therapeutics seller in Q2 2016 was Visium Asset Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q2 2016.